We are Unique
DEDICATED TO HUMAN PROGRESS
Our passion for science and technology is what drives our more than 64,000 employees in 66 countries to find solutions to some of today’s toughest challenges and create more sustainable ways to live.
We are here for people at every step, helping to create, improve and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community. Our tools, services and digital platform make research simpler, more exact, and help deliver breakthroughs more quickly. Our solutions accelerate access to health by assuring tests are accurate and the medicine we take can be trusted. We are the company behind the companies, advancing digital living. Our science sits inside technologies that are changing the way we access, store, process, and display information. Our innovations are unlocking the power and potential of data to open new possibilities to transform life on Earth as we know it.
Thanks to the constant curiosity of our employees, we are making discoveries that can change the landscape of entire industries. For more than 350 years, we have been pushing the boundaries of what is possible, and we will continue to do so in the years to come.
Our more than 64,000 colleagues around the world are driven by a common aspiration: Advancing human progress. That's what we're committed to every day – across all of our company.
Science as a force for good
Our ambition is to leverage science and technology to achieve lasting progress for mankind. For us, sustainable entrepreneurship and profitable growth go hand in hand.
Recent NewsView All News
Merck KGaA, Darmstadt, Germany, today announced a license agreement with Abbisko Therapeutics for pimicotinib (ABSK021).
We successfully integrated p-Chip's microtransponder technology as a crypto-anchor into a cyber-physical trust framework solution developed by us.
Further develops its biosafety testing laboratories for local demand; New labs complete 2nd phase of company's €29 million Biologics Testing Center.